Board summary
Key figures
23,827
Registered population
55.3% aged 18–64
25.6%
Aged 65+
ICB 19.0% · England 17.9%
5.0%
Ethnic minority (non-White)
2.3% Asian · England 9.6%
9.2%
In IMD quintile 1
ICB 31.9% · England 21.0%
~1,791
Core20 residents (est.)
Resident basis; registered basis ~2,204 · see page 3
5,270
Hypertension register
+9.71% in 3 yrs · England +5.60%
205
SMI register
5.2% of Cheshire East (LAD)'s
393
COPD register
Reviews +8.94% in 3 yrs
Forecast to 2030
6,645
Hypertension patients, 2030
+1,375 on today
67.1%
QRISK ≥20% on statins, 2030
+3.36pp over 3 yrs
8.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Lipid therapy trails England across high-risk cohorts.
Lipid-lowering therapy in CKD is 61.0% (England 70.3%), alongside shortfalls in diabetes with CVD (76.9% vs 84.4%) and QRISK ≥ 20% (59.8% vs 63.6%).
Asthma annual reviews trail England and borough.
Asthma reviews reach 61.4% against 64.5% in Cheshire East (LAD) and 65.7% in England, leaving a scale indicator of about 670 of 1,735 patients.
Hypertension target control and COPD reviews lead.
Hypertension treatment to target is 72.9% (England 70.3%; Cheshire East (LAD) 69.8%), while annual COPD reviews reach 89.3% against 76.4% in England.
Population, age and ethnicity
Older population with 25.6% aged 65+ may elevate frailty and care-home demand
Knutsford PCN serves 23,827 registered patients at Knutsford Medical Partnership. Older adults aged 65+ make up 25.6% (6,100 patients), well above Cheshire East (22.6%), the ICB (19.0%) and England (17.9%). The PCN catchment includes 15 care homes with 966 beds, while list size is projected to grow 3.8% by 2030 (unverified methodology). Census usual residents in associated areas are 95.0% White (Cheshire East 94.4%, ICB 93.0%, England 81.1%) and 5.0% ethnic minority groups. This older profile may drive high frailty and multimorbidity demand, though resident Census ethnicity does not directly measure registered-patient demographics.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average deprivation is low at decile 7.3, but 9.2% remain in Core20 areas
Knutsford PCN has an average IMD decile of 7.3 (Cheshire East 7.1, ICB 5.2, England 5.5), with 9.2% of registered patients in the Core20 cohort (Cheshire East 9.2%, ICB 31.9%, England 21.0%). This equates to 2,204 estimated registered patients at Knutsford Medical Partnership, alongside 1,791 associated residents across one decile-2 LSOA (including 465 aged 0–17 and 216 aged 65+). Validating patient addresses against resident postcodes is essential to reconcile denominators before targeting outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
205
SMI register
0.87% recorded prevalence
244
Learning disability register
1.03% recorded prevalence
15
Care homes, 966 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
The PCN records 244 learning disability patients (1.0% vs Cheshire East 0.5%, ICB 0.6%, England 0.6%) and 205 on the severe mental illness register (0.9% vs Cheshire East 0.9%, ICB 1.1%, England 1.0%). Cheshire East local authority records 8.8% unpaid carers (Census 2021) and 10 rough sleepers (autumn 2025 snapshot).
Severe mental illness: physical health checks
Recorded SMI checks show 83.4% have documented BMI, though three-year progress fell 1.3 pp (England +5.1 pp), while BP checks reached 82.3% (England 83.4%). Trailing physical recording could reflect recall gaps, unconfirmed locally.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,270
Hypertension register
+9.71%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+3.64pp
BP control, under 80
≤140/90 · −0.79pp aged 80+
+1,375
More patients by 2030
Forecast 6,645 (26.86%)
Hypertension case-finding and control
Recorded hypertension prevalence is 22.3% (5,270 patients), exceeding Cheshire East (17.3%), the ICB (16.8%) and England (15.2%), alongside elevated stroke (3.8%) and heart failure (3.3%) registers. Overall blood pressure treatment to target reaches 72.9% (England 70.3%) and control under age 80 is 71.6% (England 67.8%). However, blood pressure control for patients aged 80 and over trails at 79.8% (England 81.2%), falling 1.0% over three years (England +2.2%), alongside a 0.7% drop in recent blood pressure recording (England +3.6%). Observation periods are unstated and crude prevalence is not age-adjusted. Hypertension management is strong overall, but trailing review trends among older patients highlight a key group needing systematic blood pressure reassessment.
Lipids and statins
Lipid-lowering therapy lags behind England in QRISK ≥ 20% at 59.8% (England 63.6%), CKD at 61.0% (England 70.3%) and diabetes with CVD at 76.9% (England 84.4%), falling 1.8% over three years (England +1.0%). Fewer at-risk patients receive lipid-lowering therapy than England rates imply, making structured recall audits the immediate priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 58,968 | £1.60 | £1.71 | £1.86 | £94,349 |
| Cardiovascular (all), 2025 | 74,415 | £4.31 | £4.37 | £3.33 | £320,729 |
In 2026, the PCN prescribed 58,968 lipid-modifying items at an average cost of £1.60 per item, compared to £1.72 in Cheshire East, £1.71 in the ICB and £1.86 in England, spending £15,332 less than at England's unit cost. Lower unit costs indicate the PCN spends less per item than England, though unit cost does not establish prescribing efficiency or formulary.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.21%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.19%
Asthma prevalence, PCN 3-yr % change
Asthma recorded prevalence is 7.8% (1,735 patients), above England (6.6%), while 12-month reviews reach 61.4% (England 65.7%; Cheshire East 64.5%), leaving about 670 patients unreviewed. Conversely, COPD reviews reach 89.3% (England 76.4%), despite recorded prevalence of 1.7% (393 patients; England 1.9%, unadjusted gap +47 to +58). Prescribing of asthma management items for ages 5-19 is 1,541 per 1,000 (England 1,488). Divergent review rates could reflect differing recall protocols across disease pathways, unverified locally.
Cancer register and children's immunisation
Cancer prevalence is 6.0% (1,420 patients), above England (3.8%). In childhood immunisation (Q1 2025/26), 12-month 6-in-1 coverage is 83.9%, below the 95.0% target by 11.1 pp (England 91.0%). At age 5, MMR dose 1 reaches 96.7% but dose 2 is 88.3% (8.4 pp difference; England 82.8%). The infant shortfall and pre-school dose drop could reflect reminder timing, unconfirmed locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Knutsford PCN recorded cancer prevalence is 6.0% (1,420 patients), growing +16.7% over three years (England +9.0%, Cheshire East (LAD) +10.6%). Local screening coverage exceeds England for breast (80.9% vs 69.9%) and cervical screening aged 25–49 (76.4% vs 66.8%). In the wider system, NHS Cheshire and Merseyside ICB diagnosed 55.5% of cancers at stage 1 or 2 in 2022 (England 55.3%), below the 75.0% national ambition by 19.5 pp, representing about 2,640 extra early-stage cases across 13,490 staged tumours (72.8% known stage). Early staging varies from 40.4% in lung to 87.1% in breast cancer.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the cancer 62-day referral to treatment standard, below the 85.0% standard by 12.2 pp (East Cheshire NHS Trust 53.4%, North Cheshire and Mersey NHS Foundation Trust 83.7%, NHS Cheshire and Merseyside Integrated Care Board 76.2%, England 71.2%). On the 28-day faster diagnosis standard, the trust reached 80.1% against the 75.0% standard (East Cheshire NHS Trust 81.1%, England 79.3%). Trust diagnostic 6+ week waits were 9.0% overall (East Cheshire NHS Trust 16.2%, England 23.1%), though gastroscopy reached 29.3%.
| Pathways within standard (%) | Manchester | East Cheshire | North Cheshire and Mersey | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 81.08 | 80.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.54 | 96.30 | 98.17 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 53.41 | 83.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | East Cheshire | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 11.68 | 26.62 | 0.53 | 21.40 |
| CT | 14.66 | 11.49 | 2.32 | 9.92 |
| Echocardiography | 4.91 | 26.24 | 28.04 | 28.48 |
| Colonoscopy | 4.51 | 10.85 | 15.98 | 30.83 |
| Gastroscopy | 29.35 | 10.25 | 20.24 | 29.02 |
| All 15 DM01 tests | 8.98 | 16.17 | 6.34 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In June 2026 (provisional), Cheshire East residents recorded 135,460 community care activities and 72,825 contacts across 21,910 patients (NHS Cheshire and Merseyside Integrated Care Board: 1,332,205 activities, 541,280 contacts, 146,240 patients). Adults aged 65+ accounted for 60.8% of borough contacts, with 18,280 community referrals. These borough-level data reflect wider community demand and are not PCN activity.
Practice variation and patient experience
Single-practice clinical QOF reaches 99.7% while appointment booking trails England at 63.2%
Knutsford Medical Partnership achieved 93.1% overall QOF points (England 92.5%) and 99.7% in the clinical domain (England 97.1%) in 2025/26. However, vaccination and immunisation domain achievement reached only 41.0% (England 55.2%), while personalised care adjustments were 7.7% across all domains (England 10.0%). This highlights childhood and adult immunisation uptake as the primary operational gap.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Knutsford Medical | 173 | 9.2 | 65.3% | 63.2% | 77.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 PCN measures trail England's three-year change, led by mental health checks
Across 25 compared measures, 14 trail England's three-year trajectory. The widest percentage-point lags are in annual physical checks for patients on the severe mental illness register: recorded body mass index fell 1.3 pp (England +5.1 pp) and alcohol checks rose 0.1 pp (England +5.4 pp). Non-frail diabetes HbA1c control rose 0.1% relative (England +4.4%). Conversely, notable three-year strengths include heart failure reviews (+36.0% vs England +8.7%), learning disability register growth (+118.1% vs England +5.4%) and COPD reviews (+8.9% vs England +2.8%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BMI record (SMI)
Alcohol record (psychosis)
Diabetes HbA1c control
Hypertension BP reading
BP check (SMI)
Heart failure reviews
COPD reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (966 beds) | n/a | Schools (catchment) | 37 | n/a |
| Children's centres | 1 | 14 | Places of worship | 34 | 272 |
| Libraries | 1 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 5 | 41 | Primary academies | 7 | 78 |
| Special schools | 1 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma 12-month reviews are 61.4% (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%) on a 1,735-patient register (7.8% prevalence), leaving about 670 patients unreviewed. For discussion: the PCN could run structured asthma recall using a single template, align inhaler prescribing checks with annual reviews, and test after-school or flexible slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD register and respiratory record review
COPD QOF prevalence (all ages) is 1.7% (393 patients) against Cheshire East (LAD) 1.8%, NHS Cheshire and Merseyside Integrated Care Board 2.5% and England 1.9% (3-year change +0.9% vs England +2.6% and Cheshire East (LAD) +3.4%), giving an unadjusted benchmark gap of +47 to +58 patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Pharmacist-led lipid therapy recall audit
Lipid-lowering therapy trails England in CKD (61.0% vs 70.3%, -9.3 pp), diabetes with CVD (76.9% vs 84.4%, -7.4 pp; 3-year change -1.8% vs +1.0%) and QRISK ≥ 20% (59.8% vs 63.6%, -3.8 pp). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Core20 list and resident reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Mental health physical check recall (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Audit older hypertensive patients (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation call and recall (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Early cancer pathway collaboration (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Appointment booking audit (p9) | GPPS last request led to a booked appointment | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD register and respiratory record review (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Pharmacist-led lipid therapy recall audit (p12) | CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
